Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

LPAR1 antagonist PIPE-791 promotes remyelination in multiple sclerosis

Nov. 15, 2021

Cannabigerol derivatives have anti-inflammatory, analgesic and antiobesity potential

Nov. 12, 2021

Trivalent PROTAC SIM-1 shows enhanced BET degradation and cytotoxicity

Nov. 11, 2021

SUVN-4404091 shows efficacy in rat model of amphetamine-induced hyperlocomotion

Nov. 11, 2021

Effective attenuation of renal fibrosis with a potent HIPK2 inhibitor

Nov. 10, 2021

Viking Therapeutics' dual GLP-1/GIP receptor agonists show potential in model of obesity

Nov. 8, 2021

Discovery of HB-007, a small-molecule degrader of SUMO1

Nov. 5, 2021

MM-3122, a novel TMPRSS2 inhibitor with antiviral activity against SARS-CoV-2 and MERS-CoV

Nov. 5, 2021

Structure-based optimization identifies potent galactokinase inhibitors

Nov. 3, 2021

SAR-439883 rescues memory deficits and prevents neurodegeneration in animal models of AD

Nov. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...